Long-term survival rates more than double previous estimates for locally advanced lung cancer

Monday, September 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Phase III trial demonstrates 32 percent overall survival rate at five years following standard-dose treatment for stage III NSCLC; trial also finds no additional benefit from cetuximab



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook